157 related articles for article (PubMed ID: 10628802)
21. Analysis of central regulatory pathways in p53-deficient primary cultures of malignant fibrous histiocytoma exposed to ifosfamide.
Schlott T; Taubert H; Fayyazi A; Schweyer S; Bartel F; Korabiowska M; Brinck U
Anticancer Res; 2004; 24(6):3819-29. PubMed ID: 15736417
[TBL] [Abstract][Full Text] [Related]
22. p53 mutation and MDM2 amplification are rare even in human papillomavirus-negative cervical carcinomas.
Ikenberg H; Matthay K; Schmitt B; Bauknecht T; Kiechle-Schwarz M; Göppinger A; Pfleiderer A
Cancer; 1995 Jul; 76(1):57-66. PubMed ID: 8630877
[TBL] [Abstract][Full Text] [Related]
23. Oncogene amplification in urothelial cancers with p53 gene mutation or MDM2 amplification.
Habuchi T; Kinoshita H; Yamada H; Kakehi Y; Ogawa O; Wu WJ; Takahashi R; Sugiyama T; Yoshida O
J Natl Cancer Inst; 1994 Sep; 86(17):1331-5. PubMed ID: 8064891
[TBL] [Abstract][Full Text] [Related]
24. Altered expression and molecular abnormalities of cell-cycle-regulatory proteins in rhabdomyosarcoma.
Takahashi Y; Oda Y; Kawaguchi K; Tamiya S; Yamamoto H; Suita S; Tsuneyoshi M
Mod Pathol; 2004 Jun; 17(6):660-9. PubMed ID: 15098008
[TBL] [Abstract][Full Text] [Related]
25. Altered patterns of MDM2 and TP53 expression in human bladder cancer.
Lianes P; Orlow I; Zhang ZF; Oliva MR; Sarkis AS; Reuter VE; Cordon-Cardo C
J Natl Cancer Inst; 1994 Sep; 86(17):1325-30. PubMed ID: 8064890
[TBL] [Abstract][Full Text] [Related]
26. Beta-catenin accumulation and gene mutation in exon 3 in dedifferentiated liposarcoma and malignant fibrous histiocytoma.
Sakamoto A; Oda Y; Adachi T; Saito T; Tamiya S; Iwamoto Y; Tsuneyoshi M
Arch Pathol Lab Med; 2002 Sep; 126(9):1071-8. PubMed ID: 12204056
[TBL] [Abstract][Full Text] [Related]
27. Biochemical uncovering of mdm2/p53 complexes in liposarcomas parallels their immunohistochemical detection.
Butò S; Pierotti MA; Tamborini E; Della Torre G; Lavarino C; Rilke F; Pilotti S
Diagn Mol Pathol; 1999 Sep; 8(3):125-30. PubMed ID: 10565683
[TBL] [Abstract][Full Text] [Related]
28. Prevalences of Gs alpha, ras, p53 mutations and ret/PTC rearrangement in differentiated thyroid tumours in a Korean population.
Park KY; Koh JM; Kim YI; Park HJ; Gong G; Hong SJ; Ahn IM
Clin Endocrinol (Oxf); 1998 Sep; 49(3):317-23. PubMed ID: 9861322
[TBL] [Abstract][Full Text] [Related]
29. Human papillomavirus infection in Egyptian esophageal carcinoma: correlation with p53, p21, mdm2, C-erbB2 and impact on survival.
Bahnassy AA; Zekri AR; Abdallah S; El-Shehaby AM; Sherif GM
Pathol Int; 2005 Feb; 55(2):53-62. PubMed ID: 15693850
[TBL] [Abstract][Full Text] [Related]
30. p53 mutation, murine double minute 2 amplification, and human papillomavirus infection are frequently involved but not associated with each other in esophageal squamous cell carcinoma.
Shibagaki I; Tanaka H; Shimada Y; Wagata T; Ikenaga M; Imamura M; Ishizaki K
Clin Cancer Res; 1995 Jul; 1(7):769-73. PubMed ID: 9816044
[TBL] [Abstract][Full Text] [Related]
31. Distinction between lipoma and liposarcoma by MDM2 alterations: a case report of simultaneously occurring tumors and review of the literature.
Boltze C; Schneider-Stock R; Jäger V; Roessner A
Pathol Res Pract; 2001; 197(8):563-8. PubMed ID: 11518050
[TBL] [Abstract][Full Text] [Related]
32. P53 and MDM2 co-expression in tobacco and betel chewing-associated oral squamous cell carcinomas.
Shwe M; Chiguchi G; Yamada S; Nakajima T; Maung KK; Takagi M; Amagasa T; Tsuchida N
J Med Dent Sci; 2001 Dec; 48(4):113-9. PubMed ID: 12160248
[TBL] [Abstract][Full Text] [Related]
33. p53, p21, Rb and mdm2 oncoproteins. Expression in normal placenta, partial and complete mole, and choriocarcinoma.
Fulop V; Mok SC; Genest DR; Gati I; Doszpod J; Berkowitz RS
J Reprod Med; 1998 Feb; 43(2):119-27. PubMed ID: 9513873
[TBL] [Abstract][Full Text] [Related]
34. Cell cycle regulators in multiple myeloma: prognostic implications of p53 nuclear accumulation.
Pruneri G; Carboni N; Baldini L; Intini D; Colombi M; Bertolini F; Valentini S; Maisonneuve P; Viale G; Neri A
Hum Pathol; 2003 Jan; 34(1):41-7. PubMed ID: 12605365
[TBL] [Abstract][Full Text] [Related]
35. Molecular and immunohistochemical p53 status in liposarcoma and malignant fibrous histiocytoma: identification of seven new mutations for soft tissue sarcomas.
Taubert H; Würl P; Meye A; Berger D; Thamm B; Neumann K; Hinze R; Schmidt H; Rath FW
Cancer; 1995 Oct; 76(7):1187-96. PubMed ID: 8630896
[TBL] [Abstract][Full Text] [Related]
36. Abnormalities of the p53 MDM2 and DCC genes in human leiomyosarcomas.
Patterson H; Gill S; Fisher C; Law MG; Jayatilake H; Fletcher CD; Thomas M; Grimer R; Gusterson BA; Cooper CS
Br J Cancer; 1994 Jun; 69(6):1052-8. PubMed ID: 8198970
[TBL] [Abstract][Full Text] [Related]
37. Molecular pathology of primary and metastatic ductal pancreatic lesions: analyses of mutations and expression of the p53, mdm-2, and p21/WAF-1 genes in sporadic and familial lesions.
Ruggeri BA; Huang L; Berger D; Chang H; Klein-Szanto AJ; Goodrow T; Wood M; Obara T; Heath CW; Lynch H
Cancer; 1997 Feb; 79(4):700-16. PubMed ID: 9024708
[TBL] [Abstract][Full Text] [Related]
38. Possible association between tumor-suppressor gene mutations and hMSH2/hMLH1 inactivation in alveolar soft part sarcoma.
Saito T; Oda Y; Kawaguchi K; Takahira T; Yamamoto H; Sakamoto A; Tamiya S; Iwamoto Y; Tsuneyoshi M
Hum Pathol; 2003 Sep; 34(9):841-9. PubMed ID: 14562278
[TBL] [Abstract][Full Text] [Related]
39. Mdm2 gene amplification in gastric cancer correlation with expression of Mdm2 protein and p53 alterations.
Günther T; Schneider-Stock R; Häckel C; Kasper HU; Pross M; Hackelsberger A; Lippert H; Roessner A
Mod Pathol; 2000 Jun; 13(6):621-6. PubMed ID: 10874665
[TBL] [Abstract][Full Text] [Related]
40. Malignant peripheral nerve sheath tumours: high Ki67 labelling index is the significant prognostic indicator.
Watanabe T; Oda Y; Tamiya S; Kinukawa N; Masuda K; Tsuneyoshi M
Histopathology; 2001 Aug; 39(2):187-97. PubMed ID: 11493336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
